199 related articles for article (PubMed ID: 38409240)
1. Nucleocapsid protein-specific monoclonal antibodies protect mice against Crimean-Congo hemorrhagic fever virus.
Garrison AR; Moresco V; Zeng X; Cline CR; Ward MD; Ricks KM; Olschner SP; Cazares LH; Karaaslan E; Fitzpatrick CJ; Bergeron É; Pegan SD; Golden JW
Nat Commun; 2024 Feb; 15(1):1722. PubMed ID: 38409240
[TBL] [Abstract][Full Text] [Related]
2. Nucleoside-Modified mRNA Vaccines Protect IFNAR
Appelberg S; John L; Pardi N; Végvári Á; Bereczky S; Ahlén G; Monteil V; Abdurahman S; Mikaeloff F; Beattie M; Tam Y; Sällberg M; Neogi U; Weissman D; Mirazimi A
J Virol; 2022 Feb; 96(3):e0156821. PubMed ID: 34817199
[TBL] [Abstract][Full Text] [Related]
3. Construction and evaluation of DNA vaccine encoding Crimean Congo hemorrhagic fever virus nucleocapsid protein, glycoprotein N-terminal and C-terminal fused with LAMP1.
Hu YL; Zhang LQ; Liu XQ; Ye W; Zhao YX; Zhang L; Qiang ZX; Zhang LX; Lei YF; Jiang DB; Cheng LF; Zhang FL
Front Cell Infect Microbiol; 2023; 13():1121163. PubMed ID: 37026060
[TBL] [Abstract][Full Text] [Related]
4. Structure and Characterization of Crimean-Congo Hemorrhagic Fever Virus GP38.
Mishra AK; Moyer CL; Abelson DM; Deer DJ; El Omari K; Duman R; Lobel L; Lutwama JJ; Dye JM; Wagner A; Chandran K; Cross RW; Geisbert TW; Zeitlin L; Bornholdt ZA; McLellan JS
J Virol; 2020 Mar; 94(8):. PubMed ID: 31996434
[TBL] [Abstract][Full Text] [Related]
5. GP38-targeting monoclonal antibodies protect adult mice against lethal Crimean-Congo hemorrhagic fever virus infection.
Golden JW; Shoemaker CJ; Lindquist ME; Zeng X; Daye SP; Williams JA; Liu J; Coffin KM; Olschner S; Flusin O; Altamura LA; Kuehl KA; Fitzpatrick CJ; Schmaljohn CS; Garrison AR
Sci Adv; 2019 Jul; 5(7):eaaw9535. PubMed ID: 31309159
[TBL] [Abstract][Full Text] [Related]
6. Bovine Herpesvirus Type 4 (BoHV-4) Vector Delivering Nucleocapsid Protein of Crimean-Congo Hemorrhagic Fever Virus Induces Comparable Protective Immunity against Lethal Challenge in IFNα/β/γR-/- Mice Models.
Aligholipour Farzani T; Földes K; Hanifehnezhad A; Yener Ilce B; Bilge Dagalp S; Amirzadeh Khiabani N; Ergünay K; Alkan F; Karaoglu T; Bodur H; Ozkul A
Viruses; 2019 Mar; 11(3):. PubMed ID: 30857305
[TBL] [Abstract][Full Text] [Related]
7. Cellular localization and antigenic characterization of crimean-congo hemorrhagic fever virus glycoproteins.
Bertolotti-Ciarlet A; Smith J; Strecker K; Paragas J; Altamura LA; McFalls JM; Frias-Stäheli N; García-Sastre A; Schmaljohn CS; Doms RW
J Virol; 2005 May; 79(10):6152-61. PubMed ID: 15858000
[TBL] [Abstract][Full Text] [Related]
8. Immunization with DNA Plasmids Coding for Crimean-Congo Hemorrhagic Fever Virus Capsid and Envelope Proteins and/or Virus-Like Particles Induces Protection and Survival in Challenged Mice.
Hinkula J; Devignot S; Åkerström S; Karlberg H; Wattrang E; Bereczky S; Mousavi-Jazi M; Risinger C; Lindegren G; Vernersson C; Paweska J; van Vuren PJ; Blixt O; Brun A; Weber F; Mirazimi A
J Virol; 2017 May; 91(10):. PubMed ID: 28250124
[TBL] [Abstract][Full Text] [Related]
9. A competitive ELISA for species-independent detection of Crimean-Congo hemorrhagic fever virus specific antibodies.
Schuster I; Mertens M; Köllner B; Korytář T; Keller M; Hammerschmidt B; Müller T; Tordo N; Marianneau P; Mroz C; Rissmann M; Stroh E; Dähnert L; Hammerschmidt F; Ulrich RG; Groschup MH
Antiviral Res; 2016 Oct; 134():161-166. PubMed ID: 27623345
[TBL] [Abstract][Full Text] [Related]
10. Identification of broadly neutralizing monoclonal antibodies against Crimean-Congo hemorrhagic fever virus.
Zivcec M; Guerrero LIW; Albariño CG; Bergeron É; Nichol ST; Spiropoulou CF
Antiviral Res; 2017 Oct; 146():112-120. PubMed ID: 28842265
[TBL] [Abstract][Full Text] [Related]
11. Structural characterization of protective non-neutralizing antibodies targeting Crimean-Congo hemorrhagic fever virus.
Durie IA; Tehrani ZR; Karaaslan E; Sorvillo TE; McGuire J; Golden JW; Welch SR; Kainulainen MH; Harmon JR; Mousa JJ; Gonzalez D; Enos S; Koksal I; Yilmaz G; Karakoc HN; Hamidi S; Albay C; Spengler JR; Spiropoulou CF; Garrison AR; Sajadi MM; Bergeron É; Pegan SD
Nat Commun; 2022 Nov; 13(1):7298. PubMed ID: 36435827
[TBL] [Abstract][Full Text] [Related]
12. LDLR is an entry receptor for Crimean-Congo hemorrhagic fever virus.
Xu ZS; Du WT; Wang SY; Wang MY; Yang YN; Li YH; Li ZQ; Zhao LX; Yang Y; Luo WW; Wang YY
Cell Res; 2024 Feb; 34(2):140-150. PubMed ID: 38182887
[TBL] [Abstract][Full Text] [Related]
13. Mapping of Antibody Epitopes on the Crimean-Congo Hemorrhagic Fever Virus Nucleoprotein.
Lombe BP; Saito T; Miyamoto H; Mori-Kajihara A; Kajihara M; Saijo M; Masumu J; Hattori T; Igarashi M; Takada A
Viruses; 2022 Mar; 14(3):. PubMed ID: 35336951
[TBL] [Abstract][Full Text] [Related]
14. A DNA vaccine for Crimean-Congo hemorrhagic fever protects against disease and death in two lethal mouse models.
Garrison AR; Shoemaker CJ; Golden JW; Fitzpatrick CJ; Suschak JJ; Richards MJ; Badger CV; Six CM; Martin JD; Hannaman D; Zivcec M; Bergeron E; Koehler JW; Schmaljohn CS
PLoS Negl Trop Dis; 2017 Sep; 11(9):e0005908. PubMed ID: 28922426
[TBL] [Abstract][Full Text] [Related]
15. Heat Shock Protein 70 Family Members Interact with Crimean-Congo Hemorrhagic Fever Virus and Hazara Virus Nucleocapsid Proteins and Perform a Functional Role in the Nairovirus Replication Cycle.
Surtees R; Dowall SD; Shaw A; Armstrong S; Hewson R; Carroll MW; Mankouri J; Edwards TA; Hiscox JA; Barr JN
J Virol; 2016 Oct; 90(20):9305-16. PubMed ID: 27512070
[TBL] [Abstract][Full Text] [Related]
16. Co-Delivery Effect of CD24 on the Immunogenicity and Lethal Challenge Protection of a DNA Vector Expressing Nucleocapsid Protein of Crimean Congo Hemorrhagic Fever Virus.
Aligholipour Farzani T; Hanifehnezhad A; Földes K; Ergünay K; Yilmaz E; Hashim Mohamed Ali H; Ozkul A
Viruses; 2019 Jan; 11(1):. PubMed ID: 30658445
[TBL] [Abstract][Full Text] [Related]
17. Protective neutralizing antibodies from human survivors of Crimean-Congo hemorrhagic fever.
Fels JM; Maurer DP; Herbert AS; Wirchnianski AS; Vergnolle O; Cross RW; Abelson DM; Moyer CL; Mishra AK; Aguilan JT; Kuehne AI; Pauli NT; Bakken RR; Nyakatura EK; Hellert J; Quevedo G; Lobel L; Balinandi S; Lutwama JJ; Zeitlin L; Geisbert TW; Rey FA; Sidoli S; McLellan JS; Lai JR; Bornholdt ZA; Dye JM; Walker LM; Chandran K
Cell; 2021 Jun; 184(13):3486-3501.e21. PubMed ID: 34077751
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the cell culture based and the mouse brain derived inactivated vaccines against Crimean-Congo hemorrhagic fever virus in transiently immune-suppressed (IS) mouse model.
Pavel STI; Yetiskin H; Kalkan A; Ozdarendeli A
PLoS Negl Trop Dis; 2020 Nov; 14(11):e0008834. PubMed ID: 33226988
[TBL] [Abstract][Full Text] [Related]
19. Crimean-Congo Hemorrhagic Fever Mouse Model Recapitulating Human Convalescence.
Hawman DW; Meade-White K; Haddock E; Habib R; Scott D; Thomas T; Rosenke R; Feldmann H
J Virol; 2019 Sep; 93(18):. PubMed ID: 31292241
[TBL] [Abstract][Full Text] [Related]
20. Crimean-Congo Hemorrhagic Fever Virus Nucleocapsid Protein Augments mRNA Translation.
Jeeva S; Cheng E; Ganaie SS; Mir MA
J Virol; 2017 Aug; 91(15):. PubMed ID: 28515298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
